Flavonoids Alleviating Insulin Resistance through ... - ACS Publications

Subscriber access provided by RUTGERS UNIVERSITY

Review

Flavonoids alleviating insulin resistance through inhibition of inflammatory signaling Ning Ren, Eunhye Kim, Bo Li, Haibo Pan, Tuantuan Tong, Chung S Yang, and youying Tu J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b05348 • Publication Date (Web): 05 Jan 2019 Downloaded from http://pubs.acs.org on January 7, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 41

Journal of Agricultural and Food Chemistry

1

Flavonoids alleviating insulin resistance through inhibition of inflammatory signaling

2

Ning Ren,1,# Eunhye Kim,1,# Bo Li,1 Haibo Pan,1 Tuantuan Tong,1 Chung S. Yang, 2,* Youying

3

Tu1,*

4

1

Department of Tea Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China

5

2

Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State

6

University of New Jersey, Piscataway, NJ 08854, USA

7 8

#The

9

Corresponding Authors

10

11

authors contributed equally.

*Telephone: +86 (136) 2571-3998. E-mail: [email protected] +1 848-445-5360. E-mail: [email protected]

12

ACS Paragon Plus Environment


Page 2 of 41

13

ABSTRACT: During the past 20 years, many studies have focused on polyphenol

14

compounds for their potential beneficial health effects. Flavonoids represent a large class of

15

phenolic compounds found in fruits, vegetables, nuts, grains, cocoa, tea, and other beverages.

16

Flavonoids have shown antioxidant and anti-inflammatory activities. Given the putative

17

relationship between inflammation and insulin resistance, the consumption of flavonoids or

18

flavonoid-rich foods have been suggested to reduce the risk of diabetes by targeting inflammatory

19

signals. This is the first comprehensive review summarizing the current research progress on the

20

inhibition of inflammation and alleviation of insulin resistance by flavonoids, as well as the

21

mechanistic link between these disorders. Laboratory and human studies on the activities of major

22

flavonoids (flavones, isoflavones, flavonols, etc.) are discussed.

23 24

KEYWORDS: Flavonoid； Insulin resistance； Inflammatory signaling; IRS-1; Macrophage

2


Page 3 of 41

25


INTRODUCTION

26

Insulin resistance (IR), defined as a diminished ability of cells to respond to the stimulation

27

of insulin, is a crucial feature of pre-diabetes and is the first detectable abnormality in type 2

28

diabetes mellitus (T2DM). The prevalence of T2DM is rapidly increasing and is currently one of

29

the most challenging health problems in the world.1 In the early stage of IR, normal pancreatic

30

beta-cells increase the production of insulin to compensate for IR, and glucose utilization remains

31

relatively normal. However, when IR continues, the beta-cells gradually fail to produce sufficient

32

compensatory hyperinsulinemia, leading to insulin insufficiency, impaired glucose tolerance and

33

eventually frank T2DM.2-5 IR usually occurs in peripheral tissues such as liver, adipose, and

34

skeletal muscle.

35

Inflammation is an immune response of tissues to deal with injuries, displayed as swelling,

36

redness, pain and fever, which rely upon metabolic support and energy redistribution. Thus, the

37

basic inflammatory response favors a catabolic state, and inhibits anabolic pathways such as the

38

highly conserved and powerful insulin signaling pathway.1 In normal circumstances, inflammation

39

is a short-term process that contributes to tissue repair. However, the long-term consequences of

40

prolonged inflammation have detrimental effects.6 Intervention studies have demonstrated the

41

occurrence of inflammation in T2DM pathogenesis, especially that with IR.7

42

A correlation between IR and inflammation has been suggested since the 1990s.8 In the

43

subsequent decades, studies demonstrated a clearer association between chronic inflammatory

44

signaling and IR.9-10 Elevated levels of proinflammatory cytokines, such as tumor necrosis factor-

45

(TNF-)11-14, interleukin-6 (IL-6)12, interleukin-1 (IL-1)15 and resistin16, as well as decreased

3



Page 4 of 41

46

levels of anti-inflammatory cytokines, such as interleukin-10 (IL-10)17 and adiponectin,18-19 have

47

been reported in various diabetic and IR states.

48

Flavonoids represent a large class of more than 6000 phenolic compounds found in fruits,

49

vegetables, nuts, grains, cocoa, tea, and other beverages. Flavonoids are secondary metabolites of

50

plants and fungi, and have a 15-carbon skeleton containing two phenyl rings and a heterocyclic

51

ring. The basic structure of flavonoids is shown in Fig. 1. There are six major subgroups of

52

flavonoids with various differences in generic structure of the C ring, functional groups on the

53

rings and positions in the C ring that linked the B ring.4 A number of studies have demonstrated

54

the potential beneficial effects of flavonoids against inflammation and their implication to different

55

diseases20-23. For example, in a recent review by Leyva-Lopez et al.21, the modulation of cytokines

56

by flavonoids were extensively discussed with an emphasis on therapeutic application against

57

inflammation-related diseases. Our present review summarizes the current research progress on

58

flavonoids with an emphasis on the molecular mechanisms that link the anti-inflammatory

59

activities to the prevention or alleviation of IR. By assessing the biological activities of different

60

flavonoids in laboratory and human studies, we believe that it is prudent to consider flavonoids as

61

dietary constituents in a food-based approach for the prevention or alleviation of inflammation, IR

62

and T2DM. To our knowledge, this is the first comprehensive review on this topic.

63

FLAVONOIDS MODULATING INFLAMMATORY SIGNALING AND ALLEVIATING

64

INSULIN RESISTANCE IN LABORATORY STUDIES

65

Over the last 20 years, extensive research has focused on the health effects of plant

66

phenolics.5 Flavonoids may function as antioxidants to prevent oxidative stress. Given the putative

67

relationship between diabetes and inflammation,2, 24 and the potential for flavonoids to protect the 4


Page 5 of 41


68

body against oxidative stress and inflammation,25-26 it is plausible that flavonoids or flavonoid-

69

rich foods can lower the risk for developing IR and T2DM.27-28 Some studies are discussed below,

70

and possible sites of actions are shown in Fig. 2 and Fig. 3.

71

Flavones

72

Flavones, characterized by the backbone of 2-phenylchromen-4-one (shown in Fig. 4), are

73

found mainly in celery, parsley and different herbs.20, 22 Luteolin, tangeretin, velutin, nobileten and

74

apigenin are typical flavones that have been studied for their activities in the alleviation of

75

inflammation and IR. Some key studies are summarized in Table 1.

76

Luteolin, which is abundant in vegetables and fruits,29-31 was reported to alleviate IR through

77

inhibiting inflammation pathways. In C57BL/6 mice fed a high-fat diet (HFD), luteolin

78

supplementation suppressed inflammatory macrophage infiltration32 and mast cell infiltration33 into

79

mouse epididymal adipose tissues, possibly leading to improved insulin sensitivity. The serum

80

levels of inflammatory cytokines, TNF-α, IL- 6, and monocyte chemotactic protein-1 (MCP-1)

81

were also decreased.32-33 In addition, luteolin alleviated neuroinflammation and ameliorated

82

neuronal IR in the mouse brain by inhibiting the expression of TNF-α, IL- 1, MCP-1, resistin

83

and NF-B.34 In cell models of inflammation and IR – the inflammatory macrophages and

84

adipocyte 3T3-L1 stimulated with lipopolysaccharide (LPS) or palmitate (PA), luteolin inhibited

85

the inflammatory polarization of macrophages via activating AMPKα1 and enhanced insulin

86

signals in adipocytes.32 Luteolin also enhanced insulin sensitivity via activation of PPARγ and

87

PKC transcriptional activity in inflammatory adipocytes.33, 35 In another study, using a cell model

88

of PA-treated human umbilical vein endothelial cells (HUVECs) and PA-treated aortic ring, pre-

89

treatment of luteolin reduced inhibitor of nuclear factor kappa-B (IKKb) phosphorylation and the 5



Page 6 of 41

90

expression of TNF-α and IL-6, blocked NF-kB activation (through attenuating P65 phosphorylation),

91

inhibited the Ser/Thr phosphorylation of insulin receptor substrates-1 (IRS-1) and restored downstream

92

Ak transforming(AKT, also known as Protein kinase B)/ endothelial nitric oxide synthase (eNOS)

93

activation in endothelial cells, as well as ameliorated the insulin-mediated endothelium-dependent

94

relaxation in rat aorta.36 Interestingly, in a co-culture system of adipocytes and macrophages,

95

luteolin reduced the production of inflammatory mediators and inhibited the interaction between

96

adipocytes and macrophages via suppressing JNK phosphorylation; both events contributed to the

97

alleviation of IR.37 Luteolin was also shown to exert anti-inflammatory action by blocking LPS-

98

mediated TNF-α and IL-638 production through inhibiting NF-κB activation and the MAPK

99

pathway. Whether inhibition of NF-κB activation and mitogen-activated protein kinase (MAPK)

100

pathway by luteolin could alleviate IR in adipocytes was not investigated in the study.38

101

Tangeretin, which is prevalent in mandarin oranges and other citrus fruits, also showed anti-

102

obesity and anti-diabetic effects through inhibiting inflammation. Tangeretin decreased total

103

cholesterol and blood glucose, and regulated the expression of IL-6, leptin, MCP-1 and resistin in

104

HFD-induced obese mice, and activated AMPKα1 and GLUT4 translocation in C2C12 cells.39

105

Tangeretin also alleviated IR by regulating the secretion of insulin-sensitizing factor – adiponectin

106

and insulin-resistance factor – MCP-1 in 3T3-L1 adipocytes.40 The same results were found in

107

this model with nobiletin, another flavone isolated from citrus peels.40 Nobiletin was also reported

108

to significantly decrease proinflammatory cytokine levels in plasma and improve insulin

109

sensitivity in HFD-fed mice.41

110

Velutin, a unique flavone found in the pulp of açaí fruit (Euterpe oleracea Mart.), had a higher

111

activity than the three other flavones studied, luteolin, nobileten, and apigenin, in reducing TNF6


Page 7 of 41


112

α and IL-6 production in macrophages induced by LPS.38 Velutin also had the highest inhibitory

113

activity against NF-κB activation and the degradation of NF-κB inhibitor, as well as in inhibiting

114

the phosphorylation of MAPK P38 and JNK.38

115

Isoflavones

116

Isoflavones are commonly found in soybean and soy products (structure shown in Fig. 4).

117

The common dietary isoflavones are puerarin, genistein and daidzein.20, 22 Some reported effects

118

of isoflavones on inflammation and IR are summarized in Table 2. A study on soy isoflavones

119

(including daidzein, genistein, and glycitein) in IR rats showed that soy isoflavone could decrease

120

the body weights and improve IR through regulating the expression of adipocytokines, such as

121

adiponectin, leptin, resistin and TNF-.42

122

Genistein is found in legumes and the Chinese plants Genista tinctoria Linn.43 Genistein was

123

reported to decrease homeostasis model assessment of IR (HOMA-IR), and to improve liver

124

function and insulin sensitivity, and to ameliorate non-alcoholic fatty liver diseases in a rat model

125

of IR.44 Genistein was also reported to reverse PA-induced loss of insulin-mediated vasodilation

126

in rat aorta, and to inhibit IKKb and NF-кB activation associated with down-regulation of TNF-α,

127

IL-6 production and expression.45 Genistein helped regulate of insulin action under IR conditions

128

by inhibiting inflammation-stimulated IRS-1 serine phosphorylation in endothelial cells. These

129

results demonstrated that genistein ameliorated endothelial dysfunction implicated in IR, as well

130

as inhibiting inflammation.45 In this article, both positive and negative regulations of insulin action

131

in endothelial cells by genistein were found. Negative regulations were shown in the inhibition of

132

insulin-stimulated tyrosine phosphorylation of IRS-1 and attenuating downstream AKT by

133

genistein, which leaded to a decreased nitric oxide (NO) production in endothelial cells.45 7



Page 8 of 41

134

Daidzein also belongs to the isoflavone subclass and is commonly found in soybeans, soy-

135

based products, fruits and nuts.46 Earlier studies suggested that daidzein had anti-diabetic effects

136

in improving glucose and lipid metabolism, as well as insulin sensitivity.47-49 Daidzein

137

significantly inhibited the downregulation of adiponectin expression via molecular mechanisms

138

different from genistein.50 In inflammatory signaling, daidzein inhibited the downregulation of

139

adiponectin by restoring the TNF-α-mediated reduction of Forkhead box protein O1 (FoxO1)

140

protein expression, but not involving JNK as was shown for genistein; neither genistein nor

141

daidzein acted as agonist of PPAR.50 The only structural difference between these two compounds

142

is the hydroxyl (genistein) or hydrogen (daidzein) moiety at the R1 position (shown in Fig. 4).

143

Puerarin is extracted from Pueraria lobata (Wild.) Ohwi. It has been reported to have

144

pharmacological action in the treatment of diabetes51 and cardiovascular diseases.52-53 In high

145

glucose induced IR endothelial cells, puerarin potentiated insulin-induced differentiation of pre-

146

adipocytes to increase glucose uptake by adipocytes, and this was associated with elevated PPAR

147

expression.54 In addition, puerarin was shown to inhibit IKKb/NF-κB activation, decrease TNF-α

148

and IL-6 production, attenuate PA-induced serine phosphorylation of IRS-1, and effectively

149

restore insulin-mediated tyrosine phosphorylation of IRS-1.55

150

Flavonols

151

Flavonols, including the commonly consumed quercetin, kaempferol, isorhamnetin, fisetin,

152

and myricetin from vegetables and fruits, are the most abundant flavonoids in our diet.20, 22 Their

153

structures are shown in Fig. 5. Some studies about the effects of flavonols on inflammation and IR

154

are summarized in Table 3.

8


Page 9 of 41


155

Quercetin is one of the most common flavonoid in the human diet,20, 22 found in various fruits,

156

flowers, and tea (Camellia sinensis). The anti-obesity and anti-diabetic properties of quercetin

157

have been shown in many studies.56-60 In a HFD model of rats, dietary consumption of quercetin

158

reduced the abdominal fat, decreased oxidative stress and suppressed inflammation, suggesting

159

that the attenuation of metabolic syndrome by quercetin is associated with the anti-inflammatory

160

effect in adipose tissue.61 In mice fed a HFD, supplementation with 0.08% quercetin for 10 weeks

161

ameliorated IR associated with decreased expression of TNF- and MCP-1, together with

162

increased expression of adiponectin in serum.56 Quercetin treatment improved whole body insulin

163

sensitivity by increasing GLUT4 expression and decreasing JNK phosphorylation, as well as by

164

decreasing TNF- and iNOS expression in skeletal muscle in obese ob/ob mice.62 Quercetin also

165

prevented the downregulation of insulin-induced glucose uptake and AKT serine phosphorylation

166

by TNF-α, and reduced nuclear accumulation of NF-κB in L6 myotubes.62 In another study,

167

treatment with different concentrations of quercetin in three experimental systems, namely co-

168

culture of macrophages and adipocytes (6.25, 12.5 or 25 µM), zebrafish (6.25, 12.5 or 25 µM) and

169

mice (25, 50 or 100 mg/kg), improved IR; this effect was associated with decreased expression of

170

TNF- and MCP-1 as well as increased expression of adiponectin in serum.17 The secretion of the

171

inflammatory cytokines IL-1β and IL-6 was decreased and the anti-inflammatory IL-10 was

172

increased.17 In a study with TNF--induced primary human adipocytes, quercetin treatment

173

inhibited the activation of inflammatory cascades (JNK, NF-B) and the expression of

174

inflammatory cytokines IL-6, IL-1 and MCP-1. The treatment also attenuated the suppression of

175

PPAR and insulin-stimulated glucose uptake, as well as decreased the serine phosphorylation of

176

IRS-1 and expression of protein tyrosine phosphatase 1B (PTP-1B).63 Moreover, quercetin 9



Page 10 of 41

177

improved glucose uptake and insulin sensitivity in skeletal muscle cells via AKT and AMPK

178

signaling pathways.64

179

Myricetin is abundant in our diet. There are several publications describing its anti-

180

inflammatory and anti-diabetic properties.65-67 An earlier report indicated that injection of

181

myricetin to rats on a high fructose diet significantly improved insulin sensitivity, decreased serum

182

glucose and insulin levels, and reversed the defective expression of regulatory subunit of

183

phosphoinositide (PI) 3-kinase.67 A recent study in db/db mice showed that myricetin treatment

184

alleviated obesity and IR by activating brown adipose tissue, recruiting beige cells, increasing

185

adiponectin secretion in brown adipose tissue, and decreasing plasma TNF concentration in db/db

186

mice.68 Another study in mice fed a high-fat, high-sucrose diet showed that myricetin, given at

187

0.12% in the diet significantly reduced body weight gain and epidydimal white adipose tissue

188

weight, alleviated hypertriglyceridemia and hypercholesterolemia, ameliorated IR and reduced

189

serum proinflammatory cytokine (TNF-α, IL-6) levels.69

190

Kaempferol is abundant in different kinds of fruits and vegetables, such as apple, grape,

191

spinach, broccoli and tea.70-71 Several studies reported that kaempferol could alleviate diabetes and

192

obesity,72-73 possibly by inhibiting inflammation74-75 and improving IR via inhibiting hepatic

193

IKK/NF-κB signaling.72, 76-77 As shown in Table 3, when Type 2 diabetic rats (induced by HFD

194

for 6 weeks and then an injection of streptozotocin), were treated with kaempferol orally for 10

195

weeks, the blood lipids and insulin levels were ameliorated in a dose-dependent manner.77

196

Kaempferol also effectively improved glucose catabolism, inhibited the serine phosphorylation of

197

IRS-1, decreased the expression of IKKα and IKKβ, reduced the nuclear and cytosol levels of NF-

198

κB, and decreased the serum levels of TNF-α and IL-6.77 Another study showed that kaempferol 10


Page 11 of 41


199

and quercetin could improve insulin-stimulated glucose uptake in mature 3T3-L1 adipocytes,

200

inhibit NO production significantly in LPS treated macrophage cells in which the PPARγ was

201

overexpressed, and compete with rosiglitazone for the same binding site of PPARγ in CV-1 cells.78

202

In this case, kaempferol and quercetin showed no difference in their mechanisms of action.

203

Other flavonoids

204

Other flavonoids, such as catechins from tea, flavon-3-ols and amentoflavone, have been

205

studied for alleviation of IR. Structures of these compounds are shown in Fig. 5 and their effects

206

on inflammation and IR are summarized in Table 4.

207

Epicatechin occurs widely in plants, especially in tea plants (Camellia sinensis) as both (+)-

208

catechin and (-)-epicatechin forms. The capacity of (-)-epicatechin to prevent TNF--induced

209

activation of pro-inflammatory signaling and IR has been reported.79 In another study, it was found

210

that (-)-epicatechin suppressed the expression of NF-κB-regulated proinflammatory cytokines and

211

chemokines that contributed to IR in rats fed a high fructose diet.80 Epigallocatechin gallate

212

(EGCG) is a characteristic and major catechin in tea plants (Camellia sinensis). Its activities have

213

been extensively studied81 and are covered in other articles in this volume. In HFD-fed rats, EGCG

214

ameliorated IR, while inhibiting the expression of inflammatory cytokines and infiltration of

215

macrophages in adipose tissue.82 In PA and glucose pretreated HepG2 cells, EGCG was reported

216

to markedly decrease levels of inflammatory and oxidative stress factors, including NF-κB, TNF-

217

α, IL-6, as well as improve insulin sensitivity.83 Theaflavins, the products of oxidative

218

condensation of catechins in the manufacture of black tea, also had the ability to improve insulin

219

sensitivity.84

11



Page 12 of 41

220

Silymarin, an extract of milk thistle seed (Silybum marianum) and containing silybin,

221

silydianin and silychrisin, was found to decrease body weight, plasma lipids, inflammation, liver

222

injuries and IR induced by HFD in mice.85

223

Amentoflavone, at concentration of 13.94 µM, was reported to reduce the expression of

224

inflammatory cytokines, such as TNF-α, IL-6, and IL-8 in insulin pre-treated HepG2 cells.86 The

225

mechanisms of action may involve inhibition of PI3K-AKT signaling and the modulation of

226

glucose metabolism.

227

HUMAN STUDIES

228

In comparison to the laboratory studies described above, there are few studies on the effects

229

of flavonoids in humans. In a 2005 review on the bioavailability and bio-efficiency of

230

polyphenols in humans, 93 intervention studies were included.87 The results showed that

231

monomeric catechins (found at high concentrations in tea) increased plasma antioxidant

232

biomarkers, energy metabolism and vascular dilation. Procyanidins (oligomeric catechins

233

found in red wine, grapes, cacao, etc) had beneficial effects on the vascular system. The effects

234

of polyphenols in vivo were generally weaker than those observed in vitro. Effects on

235

inflammatory markers and IR were not observed or not investigated in these studies on

236

polyphenols.87 In a double-blind RCT for one year on 93 postmenopausal women with T2DM

237

(on medication), ingestion of flavon-3-ols (enriched in chocolate) and isoflavones improved

238

insulin sensitivity and lipoprotein status. The combined flavon-3-ol and isoflavone intervention

239

resulted in a significant reduction in estimated peripheral IR (HOMA-IR) and improvement in 12


Page 13 of 41


240

insulin sensitivity (quantitative insulin sensitivity index).88 In a prospective study of 38,018 US

241

middle-aged and older women in a follow-up of 8.8 years (332,905 person-years), the results did

242

not support the thesis that higher consumption of flavones and flavonols was associated with lower

243

risk for T2DM; however, consumption of apples and tea might be associated with decreased risk

244

for the disease.89 In a cross section study of 1,997 females, intake of total flavonols and their

245

subclasses were calculated from food frequency questionnaires. Higher anthocyanins and

246

flavone intake was associated with significantly lower peripheral IR. Higher anthocyanin

247

intake was also associated with lower levels of high-sensitivity C-reactive protein.90 In another

248

cohort study involving 124,086 men and women, subjects self-reported change in weight over

249

multiple four-year time intervals between 1986 and 2011. Higher consumption of most flavonoids

250

including anthocyanins, flavonoid polymers, flavonols and flavan-3-ols (mostly from apples,

251

pears, berries, peppers, etc), was inversely associated with body weight change over four-year time

252

intervals.91 The weight reduction could alleviate IR.

253

MECHANISTIC CONSIDERATIONS

254

Obesity is a major cause of IR and T2DM. It has been shown that chronic, low-grade

255

inflammation associated with obesity is a major cause of IR. In recent decades, many studies and

256

reviews discussed the mechanistic links among obesity, inflammation and IR.65-67 There is strong

257

evidence that T2DM is closely related to inﬂammation. Flavonoids and related compounds have

258

become a group of important agents for research in this area. Epidemiological and human

259

intervention studies have provided evidence supporting the protective role of polyphenol-rich

260

foods against chronic diseases including diabetes, cardiovascular diseases, cancer and 13



Page 14 of 41

261

neurodegenerative diseases.22 In this review, we paid special attention to the effects of flavonoids

262

on the signaling pathways that link inflammation and IR in diabetes or pre-diabetes models. To

263

our knowledge, this is the first comprehensive review on this topic.

264

Flavonoids are known to be absorbed in the small intestine, with different bioavailabities

265

dependent on the structure, and converted to methylated, glucuronidated and sulfated

266

metabolites.81, 92-94 In addition, they can be degraded by intestinal microbes. For example, EGCG

267

and other catechins can be degraded to 5-(3', 4', 5'-trihydroxyphenyl)-γ-valerolactone and 5-(3', 4'-

268

dihydroxyphenyl)-γ-valerolactone, and these metabolites generally have lower biological

269

activities than the parent compounds.94-96 Trans-resveratrol sulfates show similar anti-

270

inflammatory activities compared to their parent compounds.97 Daidzein and genistein are

271

converted to equol and 5-hydroxy-equal by gut microbes.98 Equol is known to have stronger

272

estrogenic activity than daidzein99; however, the formation of equol has no effect on the plasma

273

level of insulin-like growth factor 1.98 Thus, flavonoid metabolites may have lower, the same, or

274

higher biological activity than the parent compounds. In the studies reviewed herein, the

275

biotransformation issue was mostly not seriously considered. The activities were assumed to be

276

mainly due to the parent compounds and the contribution by their metabolites are not clear.

277

As summarized in Tables 1-4, inhibition of inflammation related cytokines and signaling

278

pathways by most of the flavonoids are correlated with the impediment of IR development. This

279

is consistent with the well-established link between inflammation and the development of IR.1, 9-

280

10

281

discussed below.

282

Intercellular mechanisms

The possible mechanisms of flavonoids inhibiting inflammation signaling and alleviating IR are

14


Page 15 of 41


283

It is known that in overfed and overweight animals, excess caloric intake results in enlarged

284

adipocytes filled with triacylglycerol. The enlarged adipocytes in a state of inflammation produce

285

MCP-1 to attract macrophages. In response to MCP-1, macrophages infiltrate adipose tissue.

286

Macrophages in inflamed adipose tissue of the M1 type, produce TNF-α, which triggers lipid

287

breakdown and fatty acids are released into the blood9-10, 100 (Fig. 2). The fatty acids released from

288

adipose tissue enter muscle cells, where they accumulate in small lipid droplets. This ectopic

289

storage of lipids causes IR, possibly by triggering lipid-activated protein kinases that inactivate

290

some element in the insulin-signaling pathway, causing glucose transporter GLUT4 to leave the

291

muscle cell surface, preventing glucose entry into muscle, and the myocytes now become IR. Some

292

of the possible actions of flavonoids are depicted in Fig.4. For example, luteolin has been shown

293

to inhibit MCP-1 and the infiltration of macrophages into adipocytes, as well as the formation of

294

macrophage M1. It can also upregulate PPAR and adiponectin, which would favor the formation

295

of macrophage M2.33, 35, 42, 69 Apparently, luteolin has been shown to have more activities than

296

other flavonoids. It is unclear whether this is because luteolin is more commonly occurring or more

297

active than other flavonoids, or it just has been used more commonly in studies.

298

Intracellular mechanisms

299

Binding of insulin to its receptor initiates the intracellular insulin action by activating the

300

tyrosine kinase on the β-subunit of insulin receptor to phosphorylate the tyrosine of IRS-1, which

301

serves as a docking protein for various effector molecules.1 However, when IRS-1 is alternatively

302

phosphorylated on serine 307, it blocks the tyrosine phosphorylation on IRS-1 (Fig.3). Since

303

some inflammatory cytokines can induce serine phosphorylation on IRS-1, this is one of the

304

most important mechanisms linking inflammatory cytokines to IR in adipocytes.1, 101-102 The main 15



Page 16 of 41

305

inflammatory cytokines and pathways, involving TNF-, IL-6, NF-B and JNK, could be

306

inhibited by flavonoids to prevent IR.23 Flavonoids have shown activities to inhibit serine

307

phosphorylation of IRS-1, while decreasing the expression of inflammatory cytokines.35,

308

Some possible sites of activation are depicted in Fig.3.

309

Structure-activity relationship

80, 82

310

Several studies compared the activities, mechanisms of action and effective dosages of

311

different flavonoids,38, 50, 64, 103 or between flavonoids and other polyphenols or natural products,63

312

to elucidate the structure-activity relationship. For example, as discussed previously, two

313

structurally related soy isoflavones, genistein and daidzein (Fig. 4), were shown to significantly

314

inhibit the downregulation of adiponectin expression via different molecular mechanisms.50

315

Another study showed that kaempferol and quercetin competed with rosiglitazone for the same

316

binding pocket of PPARγ.78 Quercetin was reported to be equally or more effective than trans-

317

resveratrol in inhibiting TNF-α–mediated inflammation and IR in primary human

318

adipocytes.63 Four different flavones: velutin, luteolin, chrysoeriol, and apigenin were used in

319

a study to investigate the structure-activity relationship in LPS-stimulated macrophages from

320

HFD-fed mice.38 The results indicated that velutin, whose structure is similar to luteolin but

321

bears two methoxy groups at 7- and 3′-positions, had the strongest inhibitory effect among

322

the four flavones, and chrysoeriol was the most ineffective one. A study that screened six

323

flavonoids, 14 flavonoid metabolites and their various combinations (0.1–10M), for ability to

324

inhibit LPS-induced TNF- secretion in THP-1 monocytes, but these authors did not screen for

325

the ability to improve insulin sensitivity of these flavonoids.104 16


Page 17 of 41


326

However, it is unclear how so many compounds with polyphenolic structures can affect the

327

similar groups of cytokines and signaling pathways as reviewed above. Even though structure-

328

activity relationships have been explored in some studies, clear structure-related activity

329

relationship and dose-response relationships have not been fully established. It is possible that,

330

because most of these actions are linked to the inflammation process, most of these changes in

331

signaling pathways are subsequent events of the suppression of inflammation by flavonoids. ROS

332

is known to promote the inflammatory process, and the antioxidant activity of flavonoids may be

333

a key contributor to most of the activities observed in the studies reviewed herein. The possibility

334

that these phenolic compounds bind directly to specific cytokines, transcription factors and

335

receptors is also possible, as has been proposed in some of the studies reviewed herein and in other

336

reviews.4, 23, 105-106 However, clues on this information derived from in vitro studies needs to be

337

interpreted with caution because of non-specific binding activities of flavonoids and the

338

bioavailability issues. The body weight-lowering effects of some flavonoids could also contribute

339

to the lowering of inflammation and IR, especially in animals fed a HFD.105

340

Because of the wide occurrence of flavonoids in fruits and vegetables, and the similar

341

activities of many of the compounds, it is likely that these flavonoids, in combination, contribute

342

to a healthy diet that impedes inflammation and the development of IR. For example, a study on

343

soy isoflavones (including daidzein, genistein, and glycitein) in IR rats showed that these

344

isoflavones could decrease the body weights and improve IR through regulating the expression of

345

adipocytokines.42 Human studies as described above also showed that dietary flavonoids, exist as

346

mixtures of different compounds, have beneficial health effects. Therefore, it is prudent to study

347

flavanoids as food constituents, rather than leads for developing pharmaceutical agents to treat 17



Page 18 of 41

348

inflammation and IR, even though the later possibility cannot be excluded. For future research, we

349

would like to suggest the following:

350 351 352

1. The molecular mechanisms by which different flavonoids exert their anti-inflammatory effects, including structure-function relationship, need to be further investigated. 2. It is important to determine whether the cytokines and signaling pathways that are

353

affected by treatments with flavonoids are direct targets of action or are subsequent events of the

354

inhibition of an upstream event.

355

3.

The dose-response relationship, the bioavailability issue and the activity due to

356

metabolites need to be studied. It is also interesting to study whether the actions of different

357

flavonoids are additive.

358

4.

The possible toxicity due to high-level intake of flavonoids needs to be studied,

359

especially when considering the development of these compounds into dietary supplements. This

360

point is well illustrated in the use of green tea extract as dietary supplements.107 Additive effects

361

between flavonoids on toxicity need to be considered.

362

ABBREVIATIONS USED

363

AKT , Ak transforming, also known as Protein kinase B; AMPKα1, AMP-activated protein

364

kinase α1; AP-1, activator protein 1; ATMs, adipose tissue macrophages; EAT, epididymis adipose

365

tissues; EGCG, Epigallocatechin gallate; eNOS, endothelial nitric oxide synthase; FoxO1,

366

Forkhead box protein O1；HFD, high-fat diet; HUVECs, human umbilical vein endothelial

367

cells; HOMA-IR, homeostasis model assessment of IR; GAL-3, Galectin-3；IR, insulin

368

resistance; GLUT4,glucose transporter 4; GTT, glucose tolerance test; IKKb, inhibitor of nuclear 18


Page 19 of 41


369

factor kappa-B; IL-1, interleukin-1; IL-6,interleukin-6; IL-10, interleukin-10; IRS-1, insulin

370

receptor substrates-1; ISI, insulin sensitive index; ITT, insulin tolerance test; JNK, c-Jun N-

371

terminal kinase; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; MAPK,

372

mitogen-activated protein kinase; NF-B, nuclear factor kappa B; NO, nitric oxide ; PA,

373

palmitate; PCM, peritoneal cavity resident macrophage ; PI3K, Phosphatidylinositol-4,5-

374

bisphosphate 3-kinase; PIG, Palmitate insulin and glucose; PKC, Protein kinase C; PPAR,

375

peroxisome proliferator-activated receptor; PTP-1B, protein tyrosine phosphatase 1B ; ROS,

376

reactive oxygen species; SOD1, superoxide dismutase 1; SOD2, Superoxide dismutase 2;T2DM,

377

type 2 diabetes mellitus; TNF- ,tumor necrosis factor-;

378

ACKNOWLEDGEMENT

379

This research was supported by key research and development projects in Zhejiang

380

Province “Industrialization model projects on exploring functional components and related

381

products from tea flowers and fruits”（2018C02012）and National key research and

382

development plan “Processing of tea products, key technology of quality control during storage

383

and equipment development” ( 2017YFD0400803) and National Natural Science Foundation of

384

China (grant no. 31501474).The research was also supported by 2016 Project of Funding

385

Municipal Project “Study on transformation of health benefits and its mechanism during white

386

tea storage”, the Fundamental Research Funds for the Central Universities, and the Fujian

387

Province “2011 Collaborative Innovation Center” Chinese Oolong Tea Project (Fujian

388

Educational Department,[2015] No.75). We thank Ms. Vi Dan of Rutgers University for her

389

assistance in the preparation of this manuscript.

19



Page 20 of 41

390

REFERENCES

391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432

1. Khodabandehloo, H.; Gorgani-Firuzjaee, S.; Panahi, G.; Meshkani, R., Molecular and cellular mechanisms linking inflammation to insulin resistance and beta-cell dysfunction. Translational Research 2016, 167 (1), 228-256. 2. Pickup, J. C., Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes care 2004, 27 (3), 813-823. 3. Gregor, M. F.; Hotamisligil, G. S., Adipocyte stress: The endoplasmic reticulum and metabolic disease. Journal of lipid research 2007, 48 (9), 1905-1914. 4. Hossain, M. K.; Dayem, A. A.; Han, J.; Yin, Y.; Kim, K.; Saha, S. K.; Yang, G. M.; Choi, H. Y.; Cho, S. G., Molecular mechanisms of the anti-obesity and anti-diabetic properties of flavonoids. International journal of molecular sciences 2016, 17 (4). 5. Barnes, S.; Prasain, J., Current progress in the use of traditional medicines and nutraceuticals. Current Opinion in Plant Biology 2005, 8 (3), 324-328. 6. Reaven, G. M., The insulin resistance syndrome: Definition and dietary approaches to treatment. Annual Review of Nutrition 2005, 25, 391-406. 7. Martinez-Herrera, M.; Silvestre, F. J.; Silvestre-Rangil, J.; Lopez-Domenech, S.; Banuls, C.; Rocha, M., Levels of serum retinol-binding protein 4 before and after non-surgical periodontal treatment in lean and obese subjects: An interventional study. Journal of clinical periodontology 2018, 45 (3), 336-344. 8. Hotamisligil, G. S.; Spiegelman, B. M., Tumor-necrosis-factor-alpha - a key component of the obesity-diabetes link. Diabetes 1994, 43 (11), 1271-1278. 9. Olefsky, J. M.; Glass, C. K., Macrophages, inflammation, and insulin resistance. In Annual review of physiology, 2010; Vol. 72, pp 219-246. 10. Esser, N.; Legrand-Poels, S.; Piette, J.; Scheen, A. J.; Paquot, N., Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes research and clinical practice 2014, 105 (2), 141-150. 11. Stephens, J. M.; Lee, J.; Pilch, P. F., Tumor necrosis factor-alpha -induced insulin resistance in 3t3-l1 adipocytes is accompanied by a loss of insulin receptor substrate1 and glut4 expression without a loss of insulin receptor-mediated signal transduction. Journal of Biological Chemistry 1997, 272 (2), 971. 12. Kern, P. A.; Ranganathan, S.; Li, C. L.; Wood, L.; Ranganathan, G., Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism 2001, 280 (5), E745-E751. 13. Teruel, T.; Hernandez, R.; Lorenzo, M., Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining akt in an inactive dephosphorylated state. Diabetes 2001, 50 (11), 2563-2571. 14. Ruan, H.; Lodish, H. F., Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-alpha. Cytokine & growth factor reviews 2003, 14 (5), 447-455. 15. Jager, J.; Gremeaux, T.; Cormont, M.; Le Marchand-Brustel, Y.; Tanti, J. F., Interleukin1 beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007, 148 (1), 241-251. 16. Petersen, K. F.; Shulman, G. I., Etiology of insulin resistance. American Journal of Medicine 2006, 119 (5), 10S-16S. 20


Page 21 of 41

433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475


17. Seo, M. J.; Lee, Y. J.; Hwang, J. H.; Kim, K. J.; Lee, B. Y., The inhibitory effects of quercetin on obesity and obesity-induced inflammation by regulation of mapk signaling. Journal of Nutritional Biochemistry 2015, 26 (11), 1308-1316. 18. Yadav, A.; Kataria, M. A.; Saini, V.; Yadav, A., Role of leptin and adiponectin in insulin resistance. Clinica Chimica Acta 2013, 417, 80-84. 19. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M. L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001, 7 (8), 941-946. 20. Crozier, A.; Jaganath, I. B.; Clifford, M. N., Dietary phenolics: Chemistry, bioavailability and effects on health. Natural product reports 2009, 26 (8), 1001-43. 21. Leyva-Lopez, N.; Gutierrez-Grijalva, E. P.; Ambriz-Perez, D. L.; Heredia, J. B., Flavonoids as cytokine modulators: A possible therapy for inflammation-related diseases. International journal of molecular sciences 2016, 17 (6). 22. Rodriguez-Mateos, A.; Vauzour, D.; Krueger, C. G.; Shanmuganayagam, D.; Reed, J.; Calani, L.; Mena, P.; Del Rio, D.; Crozier, A., Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: An update. Archives of Toxicology 2014, 88 (10), 1803-1853. 23. Babu, P. V. A.; Liu, D.; Gilbert, E. R., Recent advances in understanding the anti-diabetic actions of dietary flavonoids. Journal of Nutritional Biochemistry 2013, 24 (11), 1777-1789. 24. Duncan, B. B.; Schmidt, M. I.; Pankow, J. S.; Ballantyne, C. M.; Couper, D.; Vigo, A.; Hoogeveen, R.; Folsom, A. R.; Heiss, G., Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003, 52 (7), 1799. 25. Rice-Evans, C. A.; Miller, N. J.; Paganga, G., Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free radical biology & medicine 1996, 20 (7), 933. 26. Kandaswami, C.; Jr, E. M., Free radical scavenging and antioxidant activity of plant flavonoids. Advances in Experimental Medicine & Biology 1994, 366 (366), 351. 27. Pandey, K. B.; Rizvi, S. I., Plant polyphenols as dietary antioxidants in human health and disease. Oxidative Medicine & Cellular Longevity 2009, 2 (5), 270. 28. Bahadoran, Z.; Mirmiran, P.; Azizi, F., Dietary polyphenols as potential nutraceuticals in management of diabetes: A review. Journal of Diabetes & Metabolic Disorders 2013, 12 (1), 43. 29. Neuhouser, M. L., Dietary flavonoids and cancer risk: Evidence from human population studies. Nutrition & Cancer 2004, 50 (1), 1. 30. Miean, K. H.; Mohamed, S., Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 2001, 49 (6), 3106-12. 31. Gates, M. A.; Tworoger, S. S.; Hecht, J. L.; De Vivo, I.; Rosner, B.; Hankinson, S. E., A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 2007, 121 (10), 2225-32. 32. Zhang, L.; Han, Y. J.; Zhang, X.; Wang, X.; Bao, B.; Qu, W.; Liu, J., Luteolin reduces obesity-associated insulin resistance in mice by activating ampkalpha1 signalling in adipose tissue macrophages. Diabetologia 2016, 59 (10), 2219-28.

21



476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520

Page 22 of 41

33. Xu, N.; Zhang, L.; Dong, J.; Zhang, X.; Chen, Y.-G.; Bao, B.; Liu, J., Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice. Molecular nutrition & food research 2014, 58 (6), 1258-1268. 34. Liu, Y.; Fu, X.; Lan, N.; Li, S.; Zhang, J.; Wang, S.; Li, C.; Shang, Y.; Huang, T.; Zhang, L., Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behavioural Brain Research 2014, 267 (4), 178. 35. Ding, L.; Jin, D.; Chen, X., Luteolin enhances insulin sensitivity via activation of ppar gamma transcriptional activity in adipocytes. Journal of Nutritional Biochemistry 2010, 21 (10), 941-947. 36. Zhu, D.; Liu, K.; Yi, J.; Liu, B.; Liu, G., Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie 2011, 93 (3), 506-512. 37. Ando, C.; Takahashi, N.; Hirai, S.; Nishimura, K.; Lin, S.; Uemura, T.; Goto, T.; Yu, R.; Nakagami, J.; Murakami, S.; Kawada, T., Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting jnk activation. FEBS letters 2009, 583 (22), 3649-3654. 38. Xie, C.; Kang, J.; Li, Z.; Schauss, A. G.; Badger, T. M.; Nagarajan, S.; Wu, T.; Wu, X., The acai flavonoid velutin is a potent anti-inflammatory agent: Blockade of lps-mediated tnfalpha and il-6 production through inhibiting nf-kappab activation and mapk pathway. The Journal of nutritional biochemistry 2012, 23 (9), 1184-91. 39. Kim, M. S.; Hur, H. J.; Kwon, D. Y.; Hwang, J. T., Tangeretin stimulates glucose uptake via regulation of ampk signaling pathways in c2c12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. Molecular & Cellular Endocrinology 2012, 358 (1), 127. 40. Miyata, Y.; Tanaka, H.; Shimada, A.; Sato, T.; Ito, A.; Yamanouchi, T.; Kosano, H., Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin. Life sciences 2011, 88 (13-14), 613. 41. Kim, Y. J.; Choi, M. S.; Woo, J. T.; Jeong, M. J.; Kim, S. R.; Jung, U. J., Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity. Molecular nutrition & food research 2017, 27 (12), 3945. 42. Zhang, H. M.; Chen, S. W.; Zhang, L. S.; Feng, X. F., The effects of soy isoflavone on insulin sensitivity and adipocytokines in insulin resistant rats administered with high-fat diet. Natural Product Research 2008, 22 (18), 1637-1649. 43. Patisaul, H. B.; Jefferson, W., The pros and cons of phytoestrogens. Frontiers in Neuroendocrinology 2010, 31 (4), 400-19. 44. Mohamed Salih, S.; Nallasamy, P.; Muniyandi, P.; Periyasami, V.; Carani Venkatraman, A., Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. Journal of Diabetes 2009, 1 (4), 278-287. 45. Gao, X. J.; Liu, K.; Huang, F.; Zhang, D. Y.; Guo, X. D.; Wang, M.; Liu, B. L., Positive and negative regulation of insulin action by genistein in the endothelium. Journal of Nutritional Biochemistry 2013, 24 (1), 222-230. 46. Liggins, J.; Bluck, L. J.; Runswick, S.; Atkinson, C.; Coward, W. A.; Bingham, S. A., Daidzein and genistein content of fruits and nuts. Journal of Nutritional Biochemistry 2000, 11 (6), 326-331. 47. Kapiotis, S.; Jilma, B.; Szalay, T.; Dirnberger, E.; Wagner, O.; Eichler, H. G.; Speiser, W., Evidence against an effect of endothelin-1 on blood coagulation, fibrinolysis, and endothelial 22


Page 23 of 41

521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565


cell integrity in healthy men. Arteriosclerosis Thrombosis & Vascular Biology 1997, 17 (11), 2861. 48. Sun, A. P.; Choi, M. S.; Cho, S. Y.; Seo, J. S.; Jung, U. J.; Kim, M. J.; Sung, M. K.; Yong, B. P.; Lee, M. K., Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in c57bl/ksj- db / db mice. Life sciences 2006, 79 (12), 1207-1213. 49. Cederroth, C. R.; Vinciguerra, M.; Gjinovci, A.; Kühne, F.; Klein, M.; Cederroth, M.; Caille, D.; Suter, M.; Neumann, D.; James, R. W., Dietary phytoestrogens activate amp-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 2008, 57 (5), 117685. 50. Yanagisawa, M.; Sugiya, M.; Iijima, H.; Nakagome, I.; Hirono, S.; Tsuda, T., Genistein and daidzein, typical soy isoflavones, inhibit tnf-alpha-mediated downregulation of adiponectin expression via different mechanisms in 3t3-l1 adipocytes. Molecular nutrition & food research 2012, 56 (12), 1783-1793. 51. Hsu, F.-L.; Liu, I. M.; Kuo, D.-H.; Chen, W.-C.; Su, H.-C.; Cheng, J.-T., Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. Journal of Natural Products 2003, 66 (6), 788-792. 52. Song, X. P.; Chen, P. P.; Chai, X. S., [effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats]. Zhongguo Yao Li Xue Bao 1988, 9 (1), 55-58. 53. Cheng, Y.; Wang, L.; Tang, M.; Yin, M.; Cui, Y.; Liang, H.; Song, Y.; Hu, X.; Luo, H.; Gao, Y.; Wang, J.; Hescheler, J.; Xi, J., Effects of puerarin on cardiac differentiation and ventricular specialization of murine embryonic stem cells. Cellular Physiology and Biochemistry 2013, 32 (4), 789-800. 54. Xu, M. E.; Xiao, S. Z.; Sun, Y. H.; Zheng, X. X.; Yang, O. Y.; Chen, G., The study of anti-metabolic syndrome effect of puerarin in vitro. Life sciences 2005, 77 (25), 3183-3196. 55. Huang, F.; Liu, K.; Du, H.; Kou, J. P.; Liu, B. L., Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an ikk beta/irs-1-dependent manner. Biochimie 2012, 94 (5), 1143-1150. 56. Choi, H. N.; Jeong, S. M.; Huh, G. H.; Kim, J. I., Quercetin ameliorates insulin sensitivity and liver steatosis partly by increasing adiponectin expression in ob/ob mice. Food Science and Biotechnology 2015, 24 (1), 273-279. 57. Arias, N.; Macarulla, M. T.; Aguirre, L.; Martínez-Castaño, M. G.; Portillo, M. P., Quercetin can reduce insulin resistance without decreasing adipose tissue and skeletal muscle fat accumulation. Genes & Nutrition 2014, 9 (1), 361. 58. Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S., Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacological research 2005, 51 (2), 117-123. 59. Stewart, L. K.; Wang, Z.; Ribnicky, D.; Soileau, J. L.; Cefalu, W. T.; Gettys, T. W., Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of c57bl/6j mice during the development of diet-induced obesity. Diabetologia 2009, 52 (3), 514. 60. Kwon, O.; Eck, P.; Chen, S.; Corpe, C. P.; Lee, J. H.; Kruhlak, M.; Levine, M., Inhibition of the intestinal glucose transporter glut2 by flavonoids. Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology 2007, 21 (2), 366. 61. Panchal, S. K.; Poudyal, H.; Brown, L., Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. Journal of Nutrition 2012, 142 (6), 1026. 23



566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609

Page 24 of 41

62. Anhê, G. F.; Okamoto, M. M.; Kinote, A.; Sollon, C.; Lellis-Santos, C.; Anhê, F. F.; Lima, G. A.; Hirabara, S. M.; Velloso, L. A.; Bordin, S., Quercetin decreases inflammatory response and increases insulin action in skeletal muscle of ob/ob mice and in l6 myotubes. European journal of pharmacology 2012, 689 (1-3), 285. 63. Chuang, C. C.; Martinez, K.; Xie, G. X.; Kennedy, A.; Bumrungpert, A.; Overman, A.; Jia, W.; McIntosh, M. K., Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-alpha-mediated inflammation and insulin resistance in primary human adipocytes. American Journal of Clinical Nutrition 2010, 92 (6), 1511-1521. 64. Dai, X. Q.; Ding, Y.; Zhang, Z. F.; Cai, X. X.; Bao, L.; Li, Y., Quercetin but not quercitrin ameliorates tumor necrosis factor-alpha-induced insulin resistance in c2c12 skeletal muscle cells. Biological & pharmaceutical bulletin 2013, 36 (5), 788-795. 65. Hiermann, A.; Schramm, H. W.; Laufer, S., Anti-inflammatory activity of myricetin-3-obeta-d-glucuronide and related compounds. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1998, 47 (11), 421-7. 66. Tzeng, T. F.; Liou, S. S.; Liu, I. M., Myricetin ameliorates defective post-receptor insulin signaling via beta-endorphin signaling in the skeletal muscles of fructose-fed rats. Evidencebased complementary and alternative medicine : eCAM 2011, 2011, 150752. 67. Liu, I. M.; Tzeng, T. F.; Liou, S. S.; Lan, T. W., Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats. Life sciences 2007, 81 (21-22), 1479-88. 68. Hu, T.; Yuan, X.; Wei, G.; Luo, H.; Lee, H. J.; Jin, W., Myricetin-induced brown adipose tissue activation prevents obesity and insulin resistance in db/db mice. European journal of nutrition 2018, 57 (1), 391-403. 69. Choi, H. N.; Kang, M. J.; Lee, S. J.; Kim, J. I., Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet. Nutrition Research and Practice 2014, 8 (5), 544-549. 70. Häkkinen, S. H.; Kärenlampi, S. O.; Heinonen, I. M.; Mykkänen, H. M.; Törrönen, A. R., Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. Journal of Agricultural & Food Chemistry 1999, 47 (6), 2274-9. 71. Nirmala, P.; Ramanathan, M., Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats. European journal of pharmacology 2011, 654 (1), 75. 72. Jorge, A. P.; Horst, H.; De, S. E.; Pizzolatti, M. G.; Silva, F. R., Insulinomimetic effects of kaempferitrin on glycaemia and on 14c-glucose uptake in rat soleus muscle. ChemicoBiological Interactions 2004, 149 (2–3), 89-96. 73. Zanatta, L.; Rosso, A.; Folador, P.; Figueiredo, M. S.; Pizzolatti, M. G.; Leite, L. D.; Silva, F. R., Insulinomimetic effect of kaempferol 3-neohesperidoside on the rat soleus muscle. Journal of Natural Products 2008, 71 (4), 532-535. 74. Al-Numair, K. S.; Chandramohan, G.; Veeramani, C.; Alsaif, M. A., Ameliorative effect of kaempferol, a flavonoid, on oxidative stress in streptozotocin-induced diabetic rats. Redox Rep 2015, 20 (5), 198-209. 75. Abosalem, O. M., Kaempferol attenuates the development of diabetic neuropathic pain in mice: Possible anti-inflammatory and anti-oxidant mechanisms. Macedonian Journal of Medical Sciences 2014, 7 (3), 424-430. 24


Page 25 of 41

610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653


76. Zhang, Y.; Liu, D., Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function. European journal of pharmacology 2011, 670 (1), 325-32. 77. Luo, C.; Yang, H.; Tang, C.; Yao, G.; Kong, L.; He, H.; Zhou, Y., Kaempferol alleviates insulin resistance via hepatic ikk/nf-kappab signal in type 2 diabetic rats. International immunopharmacology 2015, 28 (1), 744-50. 78. Fang, X. K.; Gao, J.; Zhu, D. N., Kaempferol and quercetin isolated from euonymus alatus improve glucose uptake of 3t3-l1 cells without adipogenesis activity. Life sciences 2008, 82 (11-12), 615-622. 79. Vazquezprieto, M. A.; Bettaieb, A.; Haj, F. G.; Fraga, C. G.; Oteiza, P. I., (-)-epicatechin prevents tnfα-induced activation of signaling cascades involved in inflammation and insulin sensitivity in 3t3-l1 adipocytes. Archives of Biochemistry & Biophysics 2011, 527 (2), 113-8. 80. Bettaieb, A.; Prieto, M. A. V.; Lanzi, C. R.; Miatello, R. M.; Haj, F. G.; Fraga, C. G.; Oteiza, P. I., (-)-epicatechin mitigates high-fructose-associated insulin resistance by modulating redox signaling and endoplasmic reticulum stress. Free Radical Biology and Medicine 2014, 72, 247-256. 81. Yang, C. S.; Wang, H.; Sheridan, Z. P., Studies on prevention of obesity, metabolic syndrome, diabetes, cardiovascular diseases and cancer by tea. Journal of Food and Drug Analysis 2018, 26 (1), 1-13. 82. Bao, S. Q.; Cao, Y. L.; Fan, C. L.; Fan, Y. X.; Bai, S. T.; Teng, W. P.; Shan, Z. Y., Epigallocatechin gallate improves insulin signaling by decreasing toll-like receptor 4 ( tlr4)activity in adipose tissues of high- fat diet rats. Molecular nutrition & food research 2014, 58 (4), 677-686. 83. Zhang, Q.; Yuan, H.; Zhang, C.; Guan, Y.; Wu, Y.; Ling, F.; Niu, Y.; Li, Y., Epigallocatechin gallate improves insulin resistance in hepg2 cells through alleviating inflammation and lipotoxicity. Diabetes Research & Clinical Practice 2018, 142, 363. 84. Jin, D.; Xu, Y.; Mei, X.; Meng, Q.; Gao, Y.; Li, B.; Tu, Y., Antiobesity and lipid lowering effects of theaflavins on high-fat diet induced obese rats. Journal of Functional Foods 2013, 5 (3), 1142-1150. 85. Guo, Y.; Wang, S. L.; Wang, Y.; Zhu, T. H., Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharmaceutical biology 2016, 54 (12), 2995-3000. 86. Zheng, X. K.; Ke, Y. Y.; Feng, A. Z.; Yuan, P. P.; Zhou, J.; Yu, Y.; Wang, X. L.; Feng, W. S., The mechanism by which amentoflavone improves insulin resistance in hepg2 cells. Molecules 2016, 21 (5). 87. Williamson, G.; Manach, C., Bioavailability and bioefficacy of polyphenols in humans. Ii. Review of 93 intervention studies. The American Journal of Clinical Nutrition 2005, 81 (1), 243S-255S. 88. Curtis, P. J.; Sampson, M.; Potter, J.; Dhatariya, K.; Kroon, P. A.; Cassidy, A., Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year cvd risk in medicated postmenopausal women with type 2 diabetes: A 1-year, double-blind, randomized, controlled trial. Diabetes care 2012, 35 (2), 226-32. 89. Song, Y.; Manson, J. E.; Buring, J. E.; Sesso, H. D.; Liu, S., Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic 25



654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698

Page 26 of 41

inflammation in women: A prospective study and cross-sectional analysis. J Am Coll Nutr 2005, 24 (5), 376-84. 90. Jennings, A.; Welch, A. A.; Spector, T.; Macgregor, A.; Cassidy, A., Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. The Journal of nutrition 2014, 144 (2), 202-208. 91. Bertoia, M. L.; Rimm, E. B.; Mukamal, K. J.; Hu, F. B.; Willett, W. C.; Cassidy, A., Dietary flavonoid intake and weight maintenance: Three prospective cohorts of 124 086 us men and women followed for up to 24 years. 2016, 352. 92. Day, A. J.; Mellon, F.; Barron, D.; Sarrazin, G.; Morgan, M. R.; Williamson, G., Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Radic Res 2001, 35 (6), 941-52. 93. Nakamura, T.; Murota, K.; Kumamoto, S.; Misumi, K.; Bando, N.; Ikushiro, S.; Takahashi, N.; Sekido, K.; Kato, Y.; Terao, J., Plasma metabolites of dietary flavonoids after combination meal consumption with onion and tofu in humans. Molecular nutrition & food research 2014, 58 (2), 310-7. 94. Williamson, G.; Kay, C. D.; Crozier, A. J. C. R. i. F. S.; Safety, F., The bioavailability, transport, and bioactivity of dietary flavonoids: A review from a historical perspective. 2018, 17 (5), 1054-1112. 95. Meng, X. F.; Sang, S. M.; Zhu, N. Q.; Lu, H.; Sheng, S. Q.; Lee, M. J.; Ho, C. T.; Yang, C. S., Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chemical Research in Toxicology 2002, 15 (8), 1042-1050. 96. Lambert, J. D.; Rice, J. E.; Hong, J.; Hou, Z.; Yang, C. S. J. B.; letters, m. c., Synthesis and biological activity of the tea catechin metabolites, m4 and m6 and their methoxy-derivatives. 2005, 15 (4), 873-876. 97. Schueller, K.; Pignitter, M.; Somoza, V., Sulfated and glucuronated trans-resveratrol metabolites regulate chemokines and sirtuin-1 expression in u-937 macrophages. Journal of Agricultural and Food Chemistry 2015, 63 (29), 6535-6545. 98. Matthies, A.; Loh, G.; Blaut, M.; Braune, A., Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal slackia isoflavoniconvertens in gnotobiotic rats. The Journal of nutrition 2012, 142 (1), 40-6. 99. Rafii, F., The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol. Metabolites 2015, 5 (1), 56-73. 100. Nelson, D.L., Cox, M. M. Section 23.5 in “Lehninger Principles of Biochemistry” 6th ed. Freeman, New York, NY. 2000. 101. Sun, X. J.; Kim, S. P.; Zhang, D.; Sun, H.; Cao, Q.; Lu, X.; Ying, Z.; Li, L.; Henry, R. R.; Ciaraldi, T. P.; Taylor, S. I.; Quon, M. J., Deletion of interleukin 1 receptor associated kinase 1 (irak1) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscle. Journal of Biological Chemistry 2017. 102. de Luca, C.; Olefsky, J. M., Inflammation and insulin resistance. FEBS letters 2008, 582 (1), 97-105. 103. Zang, Y.; Igarashi, K.; Li, Y., Anti-diabetic effects of luteolin and luteolin-7-o-glucoside on kk-a(y) mice. Bioscience Biotechnology and Biochemistry 2016, 80 (8), 1580-1586. 104. di Gesso, J. L.; Kerr, J. S.; Zhang, Q.; Raheem, S.; Yalamanchili, S. K.; O'Hagan, D.; Kay, C. D.; O'Connell, M. A., Flavonoid metabolites reduce tumor necrosis factor-alpha 26


Page 27 of 41

699 700 701 702 703 704 705 706 707 708


secretion to a greater extent than their precursor compounds in human thp-1 monocytes. Molecular nutrition & food research 2015, 59 (6), 1143-54. 105. Yang, C. S.; Zhang, J.; Zhang, L.; Huang, J.; Wang, Y., Mechanisms of body weight reduction and metabolic syndrome alleviation by tea. Molecular nutrition & food research 2016, 60 (1), 160-174. 106. Vinayagam, R.; Xu, B. J., Antidiabetic properties of dietary flavonoids: A cellular mechanism review. Nutrition & Metabolism 2015, 12. 107. Yates, A. A.; Jr, J. W. E.; Shao, A.; Dolan, L. C.; Griffiths, J. C., Bioactive nutrients time for tolerable upper intake levels to address safety. Regulatory Toxicology & Pharmacology 2017, 84, 94.

709

27



Page 28 of 41

Figures captions

710

711

Figure 1. Basic structures of flavonoid subclasses

712

Figure 2. Mechanisms linking inflammation to insulin resistance in adipose tissue and

713

possible effects of flavonoids. Adipose tissue is infiltrated with increased numbers of

714

macrophages. These adipose tissue macrophages (ATMs) are a major source of cytokines. There

715

are two types of ATMs, M1 cells are defined as classically activated, proinflammatory

716

macrophages and M2 cells comprise an alternatively activated, anti-inflammatory macrophage

717

population. The formation of M1 and M2 depends on the expression of cytokines in adipose

718

tissue. (A) Signal transduction pathways in obesity that lead to chronic inflammation and IR,

719

and possible effects of flavonoids; (B) Signal transduction pathways that are modulated by

720

flavonoids to increase the population of M2 macrophages and increase insulin sensitivity

721

(Modified from Figure 2 of the review by Olefsky, et al.9). *Abbreviation used: GAL-3,

722

Galectin-3.

723

Figure 3. Intracellular mechanisms linking inflammation to insulin resistance and possible

724

effects of flavonoids. Activation of the insulin receptor by insulin leads to tyrosine

725

phosphorylation of IRS-1 thereby initiating signal transduction. When IRS-1 is alternatively

726

phosphorylated on serine 307, its downstream signaling ability is diminished. The activation

727

of inflammatory pathways, such as those involving NF-B and JNK, by inflammatory

728

cytokines, such as TNF- and IL-6, triggers phosphorylation on the serine 307 of IRS-1 to 28


Page 29 of 41


729

increase IR and further increase the expression of inflammatory cytokines, which sets up a

730

feed-forward process that further activate the inflammatory pathway. The sites of action by

731

flavonoids are shown by “

732

Luca, et al. 102).

” and “

”. (Modified from Figure 1 of the review by Carl de

733

Figure 4. Structures of flavones and isoflavones.

734

Figure 5. Structures of flavones and catechins

29



Page 30 of 41

Table 1. Flavones inhibit inflammatory signaling and alleviate insulin resistance Model

Insulin sensitivity and resistance

Ref

↑Insulin sensitivity (GTT&ITT)

32

↑Insulin sensitivity (GTT&ITT), ↑GLUT4 translocation

33

Luteolin 10 mg/kg ↓TNF-α，↓IL-1, ↓NF-κB (in the cortex and in diet for 16 20 weeks ↑Adiponectin, weeks and i.g. for hippocampus) ↓Resistin 4 weeks ↓Adiponectin, Tangeretin 0.02% 8 weeks ↓Leptin, ↓Resistin, ↑AMPKα1 in diet ↓IL-6, ↓MCP-1

↓HOMA-IR, ↑Plasma insulin ↑Plasma glucose, ↑Insulin sensitivity

34

↑Insulin sensitivity (GTT&ITT)

39

Mice on HFD

Nobiletin 0.02% in diet

↑Insulin sensitivity (GTT&ITT), ↓Plasma insulin, ↓Free fatty acids, 41 ↓ Total cholesterols

LPS-stimulated bone marrow mast cells from mice

Luteolin (20 μM ) 12 h

↓TNF-,↓IL-6,

PPAR,PKC related

/

33

LPS/PIGLuteolin (20 μM ) 12 h stimulated RAW264.7/PCM

↓TNF-,↓IL-6, ↓MCP-1

↑AMPKα1

/

32

Mice on HFD Mice on HFD Mice on HFD Mice on HFD

Agent and dosage Duration Cytokines Signaling/Cellular changes Luteolin 0.01% in 20 weeks ↓TNF-，↓IL-6， ↑PI3K-AKT, ↑AMPKα1, diet ↓MCP-1 ↓M1/MMe polarisation cell infiltration to Luteolin 0.01% in 12 weeks ↓TNF-，↓IL-6， ↓Mast EAT, diet ↓MCP-1 ↑PI3K-AKT

16 weeks ↓TNF-，↓IL-6, ↓IL-1

3T3-L1 adipocytes

Luteolin (20 μM) 24 h

PA-treated HUVECs

Luteolin (10 μM) 30 min

PA-treated aortic ring

0.1% w/v

Co-culture of hypertrophied 3T3-L1 and RAW 264.7

Luteolin (20 μM) 24 h

30 min

↑Leptin, ↑Adiponectin, ↓TNF-α，↓IL-6, ↓MCP-1 ↓TNF-α，↓IL-6, ↑NO /

/

↑PPAR, ↑AKT2

increase the response of glucose uptake to insulin stimulation

↓IKKb. ↓NF-κB, ↑AKT/eNOS,

↓IRS-1 serine phosphorylation

/

↓TNF-α， ↓MCP-1,↓NO

↓NF-κB, ↓JNK


35

restore PA-induced insulin-mediated 36 endothelium-dependent damaged relaxation /

37

30

Page 31 of 41

Model LPS-stimulated macrophages from HFD-fed mice

Agent and dosage Luteolin (10 µM) Apigenin (10 µM) Velutin (2.5 µM) Nobiletin(10 µM) (100 C2C12 myotube Tangeretin µM) Tangeretin (64/128μM) 3T3-L1 adipocytes Nobiletin (64/128μM)


Duration Cytokines

Signaling/Cellular changes

1h

↓MAP3K-MAP2K, ↓NF-κB

3h 4 days

↓TNF-α，↓IL-6 /

↑AMPKα1

↑Adiponectin， ↓MCP-1 ↑Adiponectin， ↓MCP-1, ↓Resistin

/

Insulin sensitivity and resistance / ↑GLUT4 translocation ↓Triglyceride accumulation /

Ref 38 39 40

*Abbreviations used: AKT , Ak transforming, also known as Protein kinase B; AMPKα1, AMP-activated protein kinase α1; EAT, epididymis adipose tissues; eNOS, endothelial nitric oxide synthase; GLUT4, glucose transporter 4; GTT, glucose tolerance test; HFD, high-fat diet; HOMA-IR, homeostasis model assessment of IR; HUVECs, human umbilical vein endothelial cells; IL-1β, interleukin-1β; IL-6,interleukin-6; IRS-1, insulin receptor substrates-1; ITT, insulin tolerance test; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; NF-κB, nuclear factor kappa B; NO, nitric oxide ; PCM, peritoneal cavity resident macrophage ;PKC, protein kinase C; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase;PIG, palmitate insulin and glucose; PPARγ, peroxisome proliferator-activated receptor γ; TNF-α,tumor necrosis factor-α; abbreviations are similar hereinafter.


31


Page 32 of 41

Table 2. Isoflavones inhibit inflammatory signaling and alleviate insulin resistance Model

Agent and dosage

Duration Cytokines

Insulin-resistant rat Insulin-resistant male rat

Soy isoflavones 450 30 days mg/kg i.g. daily Genistein 1 mg/kg 44 days i.g daily.

↑Adiponectin, ↓Resistin, ↓TNF-α ↓TNF-α，↓IL-6

PA-treated HUVECs

Genistein (10 μM)

↓TNF-α，↓IL-6

30 min

Signaling/Cellular changes / /

↓IKKb/NF-κB,

PA-treated aortic ring in vitro preadipocyte/adipocyte Puerarin (72M)

48 h

HUVECs PA-induced HUVECs

30 min

↓TNF-α，↓IL-6

↓IKKb/NF-kB,

24 h

↑Adiponectin

↓JNK, not PPARγ; ↑FoxO1 (not JNK, not PPAR)

Puerarin (10 μM)

TNF-α-induced 3T3-L1 Genistein (50 μM) Daidzein (50 μM)

/

/

/

↑PPARγ

Insulin sensitivity and resistance /

Ref.

↓Accumulation of lipids, ↓depletion of antioxidants, ↓HOMA-IR ↓IRS-1 serine phosphorylation restore the lost vasodilation ↑Preadipocyte differentiation, ↑Glucose-uptake / ↓IRS-1 serine phosphorylation / /

44

42

45

54

55 50

*Abbreviations used: PA, palmitate; FoxO1, Forkhead box protein O1; abbreviations are similar hereinafter.


32

Page 33 of 41


Table 3. Flavonols inhibit inflammatory signaling and alleviate insulin resistance Model Mice on HFD

Agent and dosage Quercetin 0.08% in diet

ob/ob mice

Quercetin 30 mg/kg i.p. every other day Quercetin 100 mg/kg in diet

Mice on HFD

Duration Cytokines Signaling/Cellular changes 10 weeks ↓TNF-α, ↓MCP-1, / ↑Adiponectin 10 weeks ↓TNF-α ↓JNK,↓iNOS

10 weeks ↓TNF-α, ↓IL-6， ↓JNK, ↓MAPK ↓IL-1,↓MCP-1, ↑IL-10 Leptin receptor- Myricetin 400 mg/kg i.g. 14 weeks ↑Adiponectin, / deficient db/db daily ↓TNF-α mice Mice on high- Myricetin 0.12% in diet 12 weeks ↑Adiponectin, / fat-high-sucrose ↓TNF-α, ↓IL-6, diet ↓Leptin Rats on high- Myricetin 1 mg/kg i.v., 3 14 days / ↑PI3K-AKT fructose diet times daily Rats on HFD with an injection of streptozotocin Zebrafish 3T3-L1 adipocytes and RAW264.7 cells

15 days 8 days

TNF-α treated Quercetin (25 μM) L6 myotube Primary human Quercetin (60 μM) adipocytes TNF-α treated Quercetin (20 μM) C2C12 cells

20 h

3T3-L1 adipocytes

3 days

Quercetin (50 μM), Kaempferol(50 μM)

1h 20 h

Ref 56

↑GLUT4, ↑Insulin sensitivity

62

↓HOMA-IR,

17

↑Insulin sensitivity;

68

↓Serum glucose, ↓serum insulin, 69 ↓HOMA-IR ↑Insulin sensitivity; ↑GLUT4 translocation; ↓Serum glucose, ↓Serum Insulin, ↓HOMA-IR; ↓IRS-1 serine phosphorylation; ↓Blood lipids and insulin; ↑Glucose-uptake, ↓IRS-1 serine phosphorylation

67

/ ↓NO generation ↓TNF-α, ↓NO, ↓NF-κB, ↓JNK, ↓MAPK ↓IL-6，↓IL-1β, ↓MCP-1, ↑IL-10, ↑Adiponectin / ↓IKKb/NF-κB, ↑AKT

↓Lipid accumulation /

17 17

↑Glucose uptake

62

↓IL-6，↓IL-1, ↓MCP-1 ↓NO

↓IRS-1 serine phosphorylation, 63 ↑Glucose uptake ↑Glucose uptake(both basal and 64 insulin stimulated glucose uptake)

Kaempferol 150 mg/kg i.g. 10 weeks ↓TNF-α，↓IL-6 daily Quercetin (25 μM) Quercetin (25 μM)

Insulin sensitivity and resistance ↓ HOMA-IR

/

↓IKKb/NF-κB,

↓NF-κB, ↓JNK, ↓MAPK, ↑PPARγ, ↓PTP-1B ↑AKT、↑AMPK, ↓ iNOS, ↓NF-κB /


77

↑Glucose uptake ( insulin 78 stimulated glucose uptake but not basal glucose uptake) 33


Model Agent and dosage LPS treated peritoneal Quercetin (50 μM), macrophage Kaempferol(50 μM) CV-1(a monkey kidney cell line)

Page 34 of 41

Duration Cytokines 24 h ↓NO

Signaling/Cellular changes /

Insulin sensitivity and resistance /

24 h

↑PPARγ

↓3T3-L1 differentiation

/

Ref 78

*Abbreviations used: MAPK, mitogen-activated protein kinase; IL-10, interleukin-10; PTP-1B, protein tyrosine phosphatase 1B; abbreviations are similar hereinafter.


34

Page 35 of 41


Table 4. Other flavonoids inhibit inflammatory signaling and alleviate insulin resistance Model

Agent and dosage

Duration

Cytokines

Signaling/Cellular changes

Rats on Highfructose diet

(-)-Epicatechin 20 mg/kg in diet

8 weeks

↓TNF-α,↓MCP-1

Rats on HFD

(-)-Epigallocatechin 16 weeks gallate 3.2 g/kg in diet

↓TNF-α, ↓IL-6,

Rats on HFD

Theaflavins 100 mg/kg i.g. daily

↓Leptin

↓PTP-1B ↑PI3K-AKT; ↓IKKb/NF-κB; ↓JNK ↓Infiltration of macrophages in adipose tissue, ↑PI3KAKT, ↓IKKb/NF-κB, /

Mice on HFD

Silymarin 60 mg/kg 18 days in diet

↓TNF-α，↓IL-6， ↓IL-1

TNF- induced 3T3-L1 cells

(-)-Epicatechin (10 μM)

↓TNF-α, ↓Resistin, ↓NF-κB , ↓MAPK, ↓IL-6, ↓MCP-1 ↓AP-1, ↑PPARγ, ↓PTP-1B, ↓JNK ↓TNF-α, /

30 days

4h

LPS-induced RAW (-)-Epicatechin 4h 267.4 cells (10 μM) HepG 2 cells (-)-Epigallocatechin 24 h gallate (50μM) HepG 2 cells Amentoflavone 36 h (13.94 μM)

/

↓TNF-α，↓IL-6， ↓NF-κB , ↓TNF-α，↓IL-6， ↓PI3K-AKT ↓IL-8

Insulin sensitivity and resistance ↓IRS-1 serine phosphorylation;

Ref

↓ HOMA-IR, ↓IRS-1 serine phosphorylation, ↑GLUT4

82

↑Insulin sensitivity (ISI)

84

↑Insulin sensitivity;

85

80

/ /

79

↑SOD1,↑SOD2, ↓ROS, 83 ↑glucose uptake, ↑GLUT2 ↑Glucose oxygenolysis, 86 glycogen synthesis, and gluconeogenesis

*Abbreviations used: AP-1, activator protein 1; ISI, insulin sensitive index; SOD1, superoxide dismutase 1; SOD2, Superoxide dismutase 2.


35


Page 36 of 41

Figures Figure 1

36


Page 37 of 41


Figure 2

37



Page 38 of 41

Figure 3

38


Page 39 of 41


Figure 4

39



Page 40 of 41

Figure 5

40


Page 41 of 41


Graphic for Table of Contents


41

Flavonoids Alleviating Insulin Resistance through ... - ACS Publications

Recommend Documents